Loading clinical trials...
Loading clinical trials...
Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year. ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Nantes University Hospital
NCT04592640 · Chronic Kidney Diseases, Calciphylaxis, and more
NCT05018221 · Calciphylaxis
NCT03032835 · Calciphylaxis, Calcific Uremic Arteriolopathy, and more
NCT06065852 · Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, and more
NCT04195906 · Calciphylaxis, Calcific Uremic Arteriolopathy
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions